Extracorporeal methods in lipid reduction pursuant to improvement in risk factors associated with atherosclerosis.
Atherosclerosis is the leading cause of death in the United States. Elevated plasma levels of low-density lipoprotein and lipoprotein(a) [Lp(a)] and subnormal levels of high density lipoprotein are risk factors in atherosclerotic coronary heart disease. Extracorporeal methods of affecting these risk factors are reviewed. The limited information on the effects of apheresis procedures on Lp(a) is discussed and extended from a kinetic modeling approach. An estimate, made of the number of patients who could be expected to benefit from extracorporeal lipid lowering, is presented.
Lobdell
D D
DD
Lobdell Development and Design, Denver, Colorado.
D001161:Arteriosclerosis / Q000097:blood / Q000628:therapy*; D006801:Humans; D008055:Lipids / Q000097:blood*; D017270:Lipoprotein(a); D008074:Lipoproteins / Q000097:blood; D010951:Plasma Exchange; D012307:Risk Factors
D008055:Lipids; D017270:Lipoprotein(a); D008074:Lipoproteins